Is Satellos Bioscience (MSCL) halal?
Satellos Bioscience (TSX: MSCL), the Toronto biotech developing SAT-3247 for Duchenne muscular dystrophy, gets a FAIL: it is pre-revenue with nil sales, so its separately disclosed finance income of US$992k (six months ended June 30, 2026) is effectively 100% of income - far above the ~5% non-compliant income ceiling. Debt is zero and the business gate passes.
The two-gate Shariah screen
Every screener on this site runs the same two gates: first, the business must be halal (no conventional insurance, banking, alcohol, gambling, weapons manufacturing, and the like); second, the financial ratios must clear (debt under roughly 33% of market cap, non-compliant income under roughly 5%).
Gate one: the business — PASSED
Satellos Bioscience Inc. (TSX: MSCL; NASDAQ: MSLE) is a clinical-stage drug development company based in Toronto, focused on restoring natural muscle repair and regeneration in degenerative muscle diseases. Its lead candidate, SAT-3247, is an orally administered small molecule AAK1 inhibitor being evaluated as a potential disease-modifying treatment for Duchenne muscular dystrophy (DMD) in two Phase 2 clinical trials - BASECAMP in pediatric participants and TRAILHEAD in adults - with an FDA Fast Track Designation for DMD and an Investigational New Drug application planned for facioscapulohumeral muscular dystrophy (FSHD) in the second half of 2026. The company was formerly known as iCo Therapeutics Inc. No non-permissible segments are disclosed anywhere in the filings reviewed - no alcohol, cannabis, gambling, conventional banking or insurance, weapons, pork, tobacco, or adult-entertainment activities. Developing medicines for degenerative muscle disease is not a flagged activity under standard AAOIFI-style screens. The business gate passes. Facts only, no fatwa.
Gate two: the ratios — FAILED
The non-compliant income gate fails. The Q2 2026 interim statements (six months ended June 30, 2026, reported in thousands of US dollars) disclose a separate "Finance income" line: US$571k for the quarter and US$992k for the six-month period. The company reports nil revenue - it is pre-revenue, with no approved product - so this finance income is effectively the company's only income, i.e. interest-type income is about 100% of income, far above the ~5% ceiling. The income is earned on the company's large cash pile: cash, cash equivalents and short-term investments of US$61.839M at June 30, 2026 (US$7.393M cash plus US$54.446M short-term investments), up from US$27.7M at year-end 2025 after a February 2026 equity offering. The debt gate passes with room to spare: total liabilities of US$5.861M at June 30, 2026 consist entirely of accounts payable and accrued liabilities, with zero interest-bearing debt - a debt-to-market-cap ratio of about 0% against a market capitalization of about C$258.63M (September 29, 2026; ~21.22M shares outstanding). All figures recomputed from the cited sources; Satellos reports in US dollars.
What other screeners say
No public Zoya, Musaffa or ShariaPortfolio coverage was found for Satellos Bioscience (MSCL/MSLE) as of October 2026: no public Zoya page is indexed for the ticker, site-scoped Musaffa searches returned nothing, and ShariaPortfolio publishes no public per-stock screening pages for it. The FAIL recorded here rests on the company's own disclosures.
The bottom line
Satellos Bioscience (MSCL) is a FAIL under this site's AAOIFI-style screening: the non-compliant income gate fails because the pre-revenue biotech's separately disclosed finance income - US$992k in the six months ended June 30, 2026 - is effectively 100% of income with nil revenue, far above the ~5% ceiling, earned on its US$61.839M cash and short-term investments pile. The debt gate passes: zero interest-bearing debt (US$5.861M total liabilities are only payables and accruals) is about 0% of a ~C$258.63M market cap. The business gate passes: SAT-3247 is an oral AAK1 inhibitor in Phase 2 trials for Duchenne muscular dystrophy (BASECAMP pediatric, TRAILHEAD adult; FDA Fast Track), with an FSHD program planned - no haram segments are disclosed. No public Zoya, Musaffa or ShariaPortfolio rating was found for this ticker as of October 2026. As with every screener here, this is a rules-based screening of published figures, not a religious ruling - consult a qualified scholar for personal guidance.
Sources
- Satellos Q2 2026 financial results (StockTitan, full 6-K statements: finance income, balance sheet)
- Satellos share structure, market cap ~C$258.63M, 21.22M shares outstanding (Streetwise Reports, September 30, 2026)
- Satellos Bioscience financials: zero revenue, zero total debt (TipRanks)
- Satellos Bioscience share price and market cap, TSX listing (Stockopedia)
Frequently asked questions
Is Satellos Bioscience stock halal?
Based on this screener's AAOIFI-style checks, Satellos fails: the pre-revenue biotech's separately disclosed finance income - US$992k in the six months ended June 30, 2026 - is effectively 100% of its income with nil revenue, far above the ~5% non-compliant income ceiling. Debt is zero and the business gate passes, but the income gate fails. This is a screening result, not investment advice or a religious ruling.
How does Satellos Bioscience score on the debt ratio?
The debt gate passes with room to spare: the June 30, 2026 interim balance sheet shows total liabilities of US$5.861M consisting only of accounts payable and accrued liabilities, with zero interest-bearing debt. Against a market capitalization of about C$258.63M (September 29, 2026), the debt-to-market-cap ratio is about 0%.
Why does a pre-revenue biotech fail the income gate?
Satellos reports no revenue at all - it is pre-revenue, developing SAT-3247 for Duchenne muscular dystrophy. Its separately disclosed finance income line (US$992k for the six months ended June 30, 2026; US$571k in Q2 alone) is therefore the company's only income. Interest-type income is effectively 100% of income, far above the ~5% ceiling, so the non-compliant income gate fails. The company holds US$61.839M in cash, cash equivalents and short-term investments, and that cash pile is what generates the income.
Does Satellos Bioscience have any haram business segments?
No: Satellos is a clinical-stage drug developer focused on restoring muscle repair and regeneration - its lead candidate SAT-3247 is an oral small-molecule AAK1 inhibitor in Phase 2 trials for Duchenne muscular dystrophy (BASECAMP pediatric, TRAILHEAD adult), with an FSHD Phase 2 planned. No alcohol, cannabis, gambling, conventional banking or insurance, weapons, pork, tobacco, or adult-entertainment activities are disclosed, so the business gate passes.
Do Zoya, Musaffa, or ShariaPortfolio rate Satellos Bioscience?
No public coverage was found as of October 2026: no public Zoya page is indexed for the ticker, site-scoped Musaffa searches returned nothing, and ShariaPortfolio publishes no public per-stock screening pages for it. The FAIL recorded here rests on the company's own disclosures.
Screened with our two-gate Shariah screening methodology (business-activity gate, then AAOIFI-style financial ratios).